Welcome to our dedicated page for Translational Development Acquisition SEC filings (Ticker: TDAC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Translational Development Acquisition's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Translational Development Acquisition's regulatory disclosures and financial reporting.
Translational Development Acquisition Corp. (TDAC) filed a current report to highlight progress on its planned merger with ProLogium Holding Inc.. The company announced that ProLogium has submitted an initial Registration Statement on Form F-4 to the SEC, an important step in the de‑SPAC process for the business combination first announced on May 27, 2026. TDAC’s CEO Michael Hoffman said the filing should give investors a fuller view of ProLogium’s history and details of the proposed transaction, though the registration statement remains subject to SEC review and potential revision. The forward‑looking statement section emphasizes numerous risks, including meeting a $250 million Minimum Cash condition, obtaining shareholder approvals, managing redemptions and financing needs, commercializing ProLogium’s solid‑state battery technology, and competing effectively after the combination.
ProLogium Holding Inc. posted on June 26, 2026 that it will appear on Bloomberg TV’s Advancements with Ted Danson; the segment airs June 27, 2026 at 8:00 PM EST. The filing describes ProLogium’s technology milestones, cites over 1,100 global patents, notes more than 800,000 cells shipped, and summarizes planned European expansion and a Dunkirk gigafactory with ramp-up expected between Q4 2028 and Q1 2029 and mass production and deliveries in Q2 2029. The communication contains forward-looking statements about a proposed business combination with Translational Development Acquisition Corp. and references a $250 million Minimum Cash closing condition that appears in the deal summary language.
Translational Development Acquisition Corp. issued a press release on June 22, 2026 reporting results of shareholder redemptions related to the shareholder vote held on June 17, 2026 about extending the deadline to consummate an initial business combination and providing information about its proposed business combination with ProLogium Holding Inc.
The press release is filed as Exhibit 99.1 and is incorporated by reference; the filing is submitted for purposes of Rule 425 and Rule 14a-12.
Translational Development Acquisition Corp. reported the results of shareholder redemptions tied to a vote extending the SPAC’s deadline to complete its initial business combination with ProLogium Holding Inc. Public shareholders redeemed 2,598,697 Class A shares, while holders of 14,651,303 redeemable Class A shares chose to remain invested. After these redemptions, approximately $156.8mm remains in the trust account, which will help support the proposed business combination if it closes. Management highlighted that about 85% of shareholders did not redeem, viewing this as support for the planned merger with ProLogium, a developer of next‑generation lithium ceramic battery technology.
ProLogium shared a corporate update highlighting technology and manufacturing progress. The company said it has delivered over 2.4 million battery cells worldwide and holds over 1,100 global patents. It described ongoing work on a gigafactory in Dunkirk, France, with ramp-up expected between Q4 2028 and Q1 2029 and formal mass production and deliveries in Q2 2029. The post reiterates ProLogium’s position as a manufacturer of next-generation lithium ceramic batteries, summarizes past milestones (including a 2024 GWh-class gigafactory and > 800,000 cells shipped in 2024), and frames future collaboration and commercialization efforts.
ProLogium and Elysian Aircraft BV signed a Memorandum of Understanding to explore next-generation battery applications for large battery-electric aircraft. The MoU frames joint assessments of standard and customized technical validation, targeting pack-level energy densities of 320-420 Wh/kg to support aircraft ranges of 750-1,000 km.
The collaboration will evaluate cell-to-pack integration, weight efficiency, safety, certification constraints, and European supply-chain localization opportunities. The companies will conduct feasibility and validation work as they discuss a potential cooperation agreement; timing and commercial terms are not disclosed.
Translational Development Acquisition Corp. obtained shareholder approval to extend the deadline to complete a business combination by up to twelve one-month periods from June 24, 2026 to June 24, 2027. This required amendments to both its charter and its investment management trust agreement.
Each one-month extension will require a deposit into the trust account of the lesser of $200,000 and $0.03 per outstanding public share, paid two days before the extension after five days’ advance notice to the trustee. At the meeting, about 79.56% of outstanding shares were represented, and all three proposals, including the extension and trust amendments, passed with 16,621,609 votes for and 809,296 against. In connection with the extension approval, holders of 2,598,697 Class A shares elected redemption at approximately $10.70 per share, totaling about $27,817,433.95, leaving 14,651,303 Class A IPO shares outstanding.
ProLogium Holding Inc. and OPmobility signed a Memorandum of Understanding to evaluate and jointly develop solid-state battery modules and packs for electric vehicle applications. The collaboration begins with electrical performance testing of ProLogium cells under agreed protocols while OPmobility leads module design, development and manufacturing.
The release discloses ProLogium cell metrics — 900 Wh/L volumetric energy density, 380 Wh/kg gravimetric energy density, 5%→80% fast charge in ~6.4 minutes, cycle life > 1,200 cycles, and > 95% discharge performance at -20°C — and states planned ramp and mass-production milestones for the Company’s overseas facility with ramp expected between Q4 2028 and Q1 2029 and mass production and deliveries in Q2 2029. Discussions will proceed within applicable competition laws and further details are to be included in the registration/proxy materials filed in connection with the proposed business combination.
Translational Development Acquisition Corp. reported that on June 12, 2026 it converted 4,657,499 Class B ordinary shares held by its sponsor into an equal number of Class A ordinary shares. These new Class A shares carry the same restrictions that applied to the Class B shares, including transfer limits, waived redemption rights and an obligation to vote in favor of an initial business combination.
After the conversion, 21,907,499 Class A ordinary shares and one Class B ordinary share were issued and outstanding. The transaction generated no cash for the company, did not change the amount in the trust account and did not alter the per-share redemption value of the public Class A shares, which was approximately $10.69 per public share as of June 12, 2026.
Prologium Holding Inc. presents a product and commercialization overview of its superfluidized all-inorganic solid-state batteries, highlighting technology, manufacturing, patents and gigafactory plans. The presentation cites >1,100 global patents, 800,000 cells shipped to date and Taoyuan capacity of 0.5 GWh in 2025, with Dunkirk targeting commercial operations and ramp toward mass production in Q2 2029.
The deck emphasizes cell-level safety (non-flammable electrolyte, 100% ceramic separator), high ionic conductivity (57 mS/cm at 25°C) and targeted gravimetric energy density of 430–470 Wh/kg. Cost and manufacturing-efficiency claims are presented as company estimates and management projections.